T he pivotal National Institute of Neurological Disorders and Stroke (NINDS) recombinant tissue plasminogen activator (rtPA) stroke trials established intravenous rtPA as a therapy for acute ischemic strokes within 3 hours of symptom onset. The NINDS trials required exclusion of patients with ischemic stroke if they had specific minor or rapidly improving symptoms. 1 This led to the rtPA (alteplase) product label broadly stating that "treatment . . . in patients with minor neurological deficit or with rapidly improving symptoms . . . has not been evaluated." In this setting, the role of intravenous rtPA for treatment of minor stroke syndromes at acute presentation remains unclear.
The NINDS trials specifically excluded ischemic stroke cases with no measurable deficit on the National Institutes of Health Stroke Scale (NIHSS) score; rapidly improving deficit; or symptoms of isolated sensory stroke, isolated ataxia, isolated dysarthria, or isolated facial weakness. 2 However, subsequent clinical guidelines have not precisely defined minor strokes or rapid improvement. For example, the American Heart Association stroke guidelines state that eligibility for rtPA requires that "neurological signs should not be minor and isolated." 3 Epidemiological studies have used the gross definition of NIHSS score Յ5 for "mild" stroke. 4, 5 Most recent stroke clinical trials exclude NIHSS scores of Ͻ5 or 6 from enrollment on the presumption that this represents the minor subgroup. 6 -9 A definition of NIHSS Յ5 for minor stroke would include all strokes explicitly excluded from the NINDS trials and 58 of the cases enrolled in the trials.
Currently, a substantial proportion (20% to 46%) of patients who present to emergency departments are not treated because their symptoms are perceived to be minor or rapidly improving. 4,10 -15 Furthermore, over half of all ischemic strokes in the United States have a NIHSS score Յ5. 5, 16 Recent data suggest that untreated patients with ischemic stroke perceived as minor (at presentation or due to improvement before the treatment decision) have substantial rates of disability. Disability or death at hospital discharge, as measured by modified Rankin Scale (mRS) score 2 to 6 or not discharged home, has been reported in the range of 25% to 64%. 11, [17] [18] [19] Disability or death at 90 days, as measured by mRS 2 to 6, has been reported in the range of 32% to 58%. 19, 20 This disability may be due to unmeasured cognitive effects of the stroke, extension of the stroke after acute presentation, or new events resulting from related comorbidities or it may be a direct result of the acutely presenting deficit. In some cases, it may be due to disability predating the incident stroke.
We sought to further characterize the minor stroke patient group with the lowest NIHSS scores (NIHSS Յ5) that was included in the NINDS rtPA Stroke Study. We reviewed their rate of inclusion in the trial, clinical presentations, and clinical outcomes in detail. This analysis was undertaken to explore the effectiveness of intravenous rtPA treatment for this subgroup of patients with stroke based on this pivotal study and to consider the need for further randomized studies.
Methods
The NINDS rtPA Stroke Study consisted of 2 randomized trials that tested the safety and efficacy of 0.9 mg/kg intravenous rtPA for acute ischemic stroke within 3 hours of symptom onset. 1 Patients were excluded from the trials if they had "rapidly improving or minor symptoms." The NINDS trialists reported the explicit exclusion of isolated symptoms of sensory loss, facial weakness, ataxia, or dysarthria, no measurable deficit on the NIHSS (ie, NIHSSϭ0), or a rapidly improving neurological deficit. 2 For the purposes of this retrospective analysis, minor strokes were defined as NIHSS Յ5 at baseline. Clinical stroke syndromes were defined based on prespecified NIHSS item score clusters as shown in Table 1 . We defined individual isolated symptoms or signs by NIHSS score and considered secondary definitions in which additional concurrent NIHSS item abnormalities were present.
Clinical outcomes were reviewed generally and within these cluster subgroups. A favorable outcome was defined as a mRS of 0 or 1 at 90 days. Poststroke intracranial hemorrhages were reviewed in each subgroup. We also investigated potential stroke extension or recurrent events as indexed by an increase in NIHSS score to Ͼ5 from baseline to 90 days or and at least a 2-point worsening in NIHSS from baseline to 2 hours and baseline to 24 hours.
Results
Over the 4 years of the trial, 17 324 patients were excluded; according to screening logs, 52% of these were excluded due to time of presentation. Of the remaining 8315, the "primary reason" for exclusion was minor symptoms for 1039 and rapid improvement for 1732. Among 624 patients enrolled in the trials, 58 cases had NIHSS scores Յ5, of which 42 were in the rtPA group and 16 were in the placebo group. 21, 22 Table 2 shows characteristics of the minor stroke group (age, sex, history of diabetes mellitus, hyperlipidemia or hypertension, atrial fibrillation, presumed etiology, stroke etiology after diagnostic testing, and time to treatment) compared with the remaining cases enrolled in the study. Subjects with minor strokes were younger and more often had small-vessel etiologies than those with more severe strokes. Cortical alone NIHSS item 9 and/or 11Ͼ0, and no other Ͼ0
Cortical PLUS NIHSS item 9 and/or 11Ͼ0, plus at least 1 other Ͼ0
Single limb severe weakness alone
Only one of the following NIHSS items 5a, 5b, 6a, or 6b Ն3; and no other limb weakness Ͼ0, and no others Ͼ0
At least 1 limb with severe weakness PLUS NIHSS item 5a, 5b, 6a, or 6b Ն3, plus at least 1 other Ͼ0
Hemimotor alone NIHSS items 4, 5a, and 6a all Ͼ0, and no others Ͼ0 OR 4, 5b, and 6b all Ͼ0, and no others Ͼ0
Hemimotor PLUS NIHSS items 4, 5a, and 6a, all Ͼ0 but not 5b or 6b, plus others Ͼ0 OR 4, 5b, and 6b all Ͼ0, but not 5a or 6a, plus at least 1 other Ͼ0
*Hemisensory alone NIHSS item 8Ͼ0, plus no others Ͼ0
Hemisensory PLUS NIHSS item 8Ͼ0 with at least 1 other Ͼ0
Unilateral leg weakness alone NIHSS item 6a or 6b Ͼ0, but not both 6a and 6b, and no others Ͼ0
Unilateral leg weakness PLUS
NIHSS item 6a or 6b Ͼ0, but not both 6a and 6b, and not 4 or 5, plus at least 1 other Ͼ0
*Limb ataxia alone NIHSS item 7Ͼ0, and no other Ͼ0
Limb ataxia PLUS NIHSS item 7Ͼ0, plus at least 1 other Ͼ0
Vision loss alone (NIHSS item 3Ͼ0, and no other Ͼ0)
NIHSS item 3 Ͼ0, and no other Ͼ0
Vision loss PLUS NIHSS item 3Ͼ0, plus at least 1 other Ͼ0
*Facial droop alone NIHSS item 4Ͼ0, and no other Ͼ0
Facial droop PLUS NIHSS item 4Ͼ0, plus at least 1 other Ͼ0
*Dysarthria alone NIHSS item 10Ͼ0, and no other Ͼ0
Dysarthria PLUS NIHSS item 10Ͼ0, plus at least 1 other Ͼ0
*NIHSSϭ0
May include isolated vertigo, truncal ataxia *Explicitly excluded in the NINDS trials. †NIHSS items: 1a, level of consciousness (LOC); 1b, LOC questions of month and age; 1c, LOC commands of eyes and grip; 2, best gaze; 3, visual fields; 4, facial palsy; 5a, left arm; 5b, right arm; 6a, left leg; 6b, right leg; 7, limb ataxia; 8, sensory; 9, best language; 10, dysarthria; 11, extinction. Table 3 shows the number of patients within each NIHSS symptom cluster; this categorization allows for the same patient to be in Ͼ1 cluster. Among the 58 cases that were enrolled, only 2 had isolated aphasias, and only 3 had isolated vision loss. No patients were enrolled with isolated motor symptoms, isolated severe limb weakness, isolated facial droop, isolated ataxia, dysarthria, isolated sensory symptoms, or isolated with only symptoms/signs not captured by the NIHSS score (ie, NIHSSϭ0).
The Figure shows overall distribution of 90-day mRS scores in rtPA and placebo groups. Minimal or no disability (mRS 0 or 1) was seen in 33 of 42 (78.6%; 95% CI, 63.2 to 89.7%) of rtPA cases and 13 of 16 (81.3%; 95% CI, 54.4% to 96.0%) of the placebo cases. No treatment effect (OR, 0.85; 95% CI, 0.20 to 3.63) was demonstrated when comparing favorable outcomes between the 2 arms of the trial in this underpowered (␤ Ͻ25%) post hoc analysis. It should be noted that 4 of the 58 minor strokes had baseline disability (mRS Ն2), and all were in the rtPA group. There was 1 symptomatic intracranial hemorrhage (2.4%) in the intravenous rtPA arm; this subject had a baseline NIHSS score of 3 due to isolated left leg weakness and subsequently died. There were no symptomatic hemorrhages in the placebo group, and there were no asymptomatic intracranial hemorrhages in either group. Neurological worsening was numerically, but nonsignificantly, less frequent in rtPA versus placebo arms based on NIHSS Ͼ5 at 90 days (6.3% versus 9.5%; see subgroups in Table 3 ), 2-point worsening at 2 hours (4.8% versus 18.8%), and 2-point worsening at 24 hours (11.9% versus 25%).
Discussion
Among the 624 patients in the NINDS trial, only 58 (9.3%) had NIHSS scores of Յ5. Consistent with the NINDS trialists' description of the explicit exclusions, no patients with isolated ataxia, dysarthria, facial weakness, sensory symptoms, or isolated symptoms/signs not captured by the NIHSS score (ie, NIHSSϭ0) were enrolled. However, there were only Յ3 patients enrolled with each of the isolated deficits that were not explicit exclusions in the NINDS trials.
The contrast between the proportion of minor strokes in the NINDS trials (9%) and recent epidemiological data that suggest that minor strokes (NIHSS Ͻ6) comprise between 20% and 46% of strokes that arrive within 3 hours to hospital emergency departments seems greater than can be readily explained by the explicit exclusions of the NINDS trials. Furthermore, our analysis of clinical syndromes enrolled in the NINDS trials suggests that many key syndromes were not well represented. Some syndromes were not included in the trial due to the explicit requirement of their exclusion, but others seen in the emergency setting (pure motor hemiparesis, isolated aphasias, isolated homonymous hemianopsia) were not included in any significant number despite no explicit exclusion from the trial. The relative absence of minor strokes in the NINDS trials may be due, in part, to factors specific to the era of the trials (early 1990s). Emergency physicians and triage nurses may not have recognized these presentations as strokes, because the trial took place before any proven therapy for stroke that would warrant routine acute evaluations. It is also possible that there has been a shift in the proportion of patients with minor symptoms presenting early to emergency departments either due to changing characteristics of the disease over time or to increased public awareness to present to medical care emergently.
Perhaps most significantly, whereas only 58 patients with minor symptoms were enrolled, 2971 patients were excluded due to "rapidly improving" or "minor symptoms" as the primary reason. 21 There may have been a perception among at least some of the NINDS trial investigators that these syndromes were unlikely to be disabling, leading to their exclusion from the trial. This conservative approach would have been reasonable at the time given rtPA's novelty as a stroke therapy and the lack of definitive data on its benefit and safety. The current literature suggests that minor strokes are often associated with substantial disability, but the natural history of minor ischemic stroke based on specific clinical syndromes is still not known.
It has been previously reported that there were no treatment-by-stroke severity interactions in the NINDS trials, which suggests that patients with minor stroke whose symptoms match those enrolled in the NINDS study should be treated with lytic therapy. 22 Of note, however, our retrospective analysis of minor stroke clinical syndromes suggests this subgroup in the NINDS study is not fully generalizable to the broader minor stroke patient group who may be encountered acutely both because of explicit exclusions and possible implicit exclusions.
The minor strokes in the NINDS trial in this analysis, defined by NIHSS Յ5, that were included did surprisingly well compared with the proportions of favorable outcomes among minor stroke subgroups recently reported. 22 In addition to the possibility that the patients with minor stroke enrolled in the trial are not representative of patients now arriving in emergency departments with minor symptoms, it should be kept in mind that the small number of patients in this subgroup leads to wide 95% CIs for the rate of favorable outcome.
It should also be noted that the NINDS rtPA study investigators have previously explored 5 minor stroke definitions that are different from that examined in this analysis. 2 Definition A required 0 or 1 scores on every baseline pretreatment NIHSS score item except level of consciousness, Definition B consisted of all presumed small-vessel occlusive patients, Definition C consisted of only motor deficits (including dysarthria and/or ataxia) with or without sensory deficits, Definition D required the lowest quartile of stroke severity in the NINDS trial (NIHSS Ͻ10) and no cortical or level of consciousness symptoms, and Definition E required only the lowest quartile of stroke severity in the NINDS trial (NIHSS Ͻ10). This exploratory analysis showed favorable treatment effects of rtPA across all of these definitions. However, because these definitions all included patients with NIHSS Ͼ5, they cannot be readily applied to the subgroup of interest in this analysis.
In clinical practice at this time, a large number of patients with minor stroke symptoms as defined by an NIHSS Ͻ5 are not treated with thrombolysis. For example, in the American Heart Association Get With the Guidelines Registry from 2003 to 2009, among 73 044 cases arriving to emergency departments within 2 hours and not treated with rtPA, 29 612 (41%) were not treated due to mild or improving symptoms, and 75% of these had a baseline NIHSS Ͻ5. 15 Leading stroke centers vary in their approach to acute treatment of patients with minor symptoms. Many do not treat minor symptoms unless the evaluating stroke physician perceives the symptoms at presentation to be disabling for individual circumstances. Others treat minor syndromes that have proximal arterial occlusions on intracranial vascular imaging, because these are the most likely to have poor outcomes. 23, 24 Still others treat most minor syndromes with the rationale that risk is likely to be low, and that even small-vessel events have significant disability rates and are likely to benefit from thrombolytic treatment. 1, 2 The appropriate approach to strokes with low NIHSS scores is debatable.
In summary, this exploratory analysis suggests that the NINDS trials excluded a substantial number of strokes with minor presentations, those minor stroke syndromes that were included were small in number, and conclusions about outcomes based on specific clinical syndromes cannot be drawn. Further study of this subgroup is needed in larger data sets that have systematically and prospectively included minor strokes. Whether thrombolysis is of benefit to this subgroup of patients excluded from the NINDS study is uncertain.
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